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Abstract: The COVID-19 pandemic has created a major alteration in the medical literature including the sepsis discussion. From
the outset of the pandemic, various reports have indicated that although there are some unique features pertinent to COVID-19,
many of its acute manifestations are similar to sepsis caused by other pathogens. As a consequence, the old definitions now require
consideration of this new etiologic agent, namely SARS-CoV-2. Although the pathogenesis of COVID-19 has not been fully explained,
the data obtained so far in hospitalized patients has revealed that serum cytokine and chemokine levels are high in severe COVID-19
patients, similar to those found with sepsis. COVID-19 may involve multiple organ systems. In addition to the lungs, the virus has
been isolated from blood, urine, faeces, liver, and gallbladder. Results from autopsy series in COVID-19 patients have demonstrated a
wide range of findings, including vascular involvement, congestion, consolidation, and hemorrhage as well as diffuse alveolar damage
in lung tissue consistent with acute respiratory distress syndrome (ARDS). The presence of viral cytopathic-like changes, infiltration of
inflammatory cells (mononuclear cells and macrophages), and viral particles in histopathological samples are considered a consequence
of both direct viral infection and immune hyperactivation. Thromboembolism and hyper-coagulopathy are other components in the
pathogenesis of severe COVID-19. Although the pathogenesis of hypercoagulability is not fully understood, it has been pointed out that
all three components of Virchow’s triad (endothelial injury, stasis, and hypercoagulable state) play a major role in contributing to clot
formation in severe COVID-19 infection. In severe COVID-19 cases, laboratory parameters such as hematological findings, coagulation
tests, liver function tests, D-dimer, ferritin, and acute phase reactants such as CRP show marked alterations, which are suggestive of a
cytokine storm. Another key element of COVID-19 pathogenesis in severe cases is its similarity or association with hemophagocytic
lymphohistiocytosis (HLH). SARS-CoV-2 induced cytokine storm has significant clinical and laboratory findings overlapping with
HLH. Viral sepsis has some similarities but also some differences when compared to bacterial sepsis. In bacterial sepsis, systemic
inflammation affecting multiple organs is more dominant than in COVID-19 sepsis. While bacterial sepsis causes an early and sudden
onset clinical deterioration, viral diseases may exhibit a relatively late onset and chronic course. Consideration of severe COVID-19
disease as a sepsis syndrome has relevance and may assist in terms of determining treatments that will modulate the immune response,
limit intrinsic damage to tissue and organs, and potentially improve outcome.
Key words: COVID-19, sepsis, multiorgan failure, dysregulated immune response, hyperinflammation, cytokine storm

1. Introduction
Sepsis is the most common cause of emergency admission
to the intensive care unit (ICU) and one of the major
reasons for death among hospitalized patients in ICU
[1,2]. The first sepsis definition was introduced in the early
1990s, and it has been updated over time by Surviving
Sepsis Campaign (SSC) [3]. The current definition alludes
to sepsis as a life-threatening organ dysfunction caused
by a dysregulated host response to infection. However,
the definition of sepsis is a complex issue, and it should
be emphasized that sepsis is a clinical syndrome that

is determined by the characteristics of both causative
pathogens and patients (including such variables as age,
gender, genetics, and underlying disease). The terminology
regarding sepsis is changing over time and is likely to
further evolve based on new insights, as well as the
detection of new pathogens and diagnostic tools. Although
sepsis can occur as a result of a viral etiology, viruses have
not been as prominently implicated in the etiology as have
other pathogens such as bacteria and fungi, until recently.
The COVID-19 pandemic has created a major alteration
in the medical literature including the sepsis discussion.
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Therefore, the old definitions now require consideration of
this new etiologic agent, namely SARS-CoV-2.
The current definition of sepsis is focused on the
inflammatory basis of the disease. Accumulating data
on the pathophysiology of sepsis emphasizes that sepsis
results from an imbalanced host reaction between the
proinflammatory and antiinflammatory response to
infection [4,5]. Although the pathogenesis of COVID-19
has been not fully explained, the data obtained so far in
hospitalized patients has revealed that serum cytokine
and chemokine levels are high in severe COVID-19
patients, similar to those found with sepsis [6–9]. Sepsis
associated with COVID-19 is a topic that has recently been
particularly emphasized [10]. Some researchers state that
severe and critically ill patients meet the diagnostic criteria
for sepsis and septic shock according to the Sepsis-3
International Consensus and recommend using the term
‘viral sepsis’ instead of the terms severe and critical illness
because it is more appropriate [10,11].
2. Definition and etiology of sepsis
2.1. Definition
Sepsis is a severe potentially fatal clinical syndrome and
is one of the leading causes of infection-associated death.
Early recognition and effective management may provide
improved outcomes [12]. The American College of Chest
Physicians and the Society of Critical Care Medicine
(SCCM) held a Consensus Conference on the definition
of sepsis and published a paper in 1992, following which
the definition of sepsis has been updated several times [3].
Sepsis is now defined as a life-threatening organ dysfunction
caused by a dysregulated host response to infection in the
2016 update of the SSC guideline. Currently, the use of
the sequential organ failure assessment (SOFA) score is
recommended to identify both sepsis and septic shock.
The SOFA score contains evaluation parameters pertaining
to six organ systems including respiration, coagulation,
liver, central nervous system, renal, and the circulatory
system [1]. An acute change in total SOFA score ≥ 2
points according to the baseline assessment consequent
to the infection is accepted as organ dysfunction, which
is associated with an in-hospital mortality greater than
10%. In patients not known to have preexisting organ
dysfunction, the baseline SOFA score is considered as zero.
Septic shock is defined as the need for vasopressor therapy
to maintain mean arterial pressure ≥ 65 mmHg despite
adequate fluid resuscitation, and a lactate level >2 mmol/L
in patients with sepsis. This condition has been reported
to be associated with hospital mortality rates that may
exceed 40% [13]. In 2016, a bedside clinical score, quick
SOFA (qSOFA), was also developed. The qSOFA score
consists of three parameters: respiratory rate of ≥22/min,
altered mentation, and systolic blood pressure of ≤100 mm
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Hg. In ambulatory settings, emergency departments, or
hospital wards, patients who are suspected to have sepsis
can be easily evaluated utilizing the qSOFA score for poor
outcomes. Patients who meet at least two of the criteria are
considered candidates at risk for the development of sepsis
and should be evaluated with the SOFA score.
In sepsis, two consecutive phases are seen, the initial
phase being a hyper-inflammatory phase, which is then
followed by an immunosuppressive phase [4]. There are
numerous markers in the hyperinflammatory phase such
as C-reactive protein (CRP), procalcitonin, tumor necrosis
factors (TNF), interleukin (IL) 1β, and IL-6. TNF, IL-1β,
and IL-6, which are pro-inflammatory cytokines and
released as the initial response to injury or infection. CRP
production is stimulated by IL-6 and is produced by the
liver as a response to infection. Procalcitonin is produced
in many cells of the body and considered to be the most
useful marker severe systemic inflammation. Several of
these markers are accepted as the biomarkers of sepsis and
may be used to assist in the diagnosis and management of
patients with sepsis [14]. Similarly, these markers have also
been documented to be increased in patients with severe
COVID-19 [6–8,10].
2.2. Etiology
Sepsis can develop secondary to bacteria, viruses, fungi,
and other pathogens, with bacterial pathogens being most
frequently implicated [15]. In a recent comprehensive
study investigating sepsis etiology, the Extended
Prevalence of Infection in Intensive Care II (EPIC II),
the most common infection sites were determined to
be the lungs (64%), abdomen (20%), and bloodstream
(15%). The most common pathogens were gram-negative
bacteria (62%), gram-positive cocci (47%), and fungi
(19%) [16]. In another study evaluating communityacquired and hospital-acquired sepsis and septic shock,
the most common infection sites were lungs, abdomen,
and bloodstream in both groups. The most common
pathogens isolated in this study included Streptococcus
pneumoniae, Escherichia coli, and other gram-positive and
gram-negative bacteria in community-acquired sepsis,
and Staphylococcus aureus, nonfermentative, and other
gram-positive and gram-negative bacteria in hospitalacquired sepsis [17].
In up to 42% of sepsis cases, no bacteria is isolated,
suggesting that sepsis may be of a nonbacterial etiology.
However, the proportion of viruses that have been
implicated is very low, accounting for approximately
1% of reported sepsis cases [17]. However, recent
reports emphasized that respiratuar viruses have been
underestimated in sepsis and septic shock [18]. Influenza
viruses, adenoviruses, and dengue viruses all have the
capacity to cause viral sepsis. Influenza A and B viruses may
cause severe infection in children younger than 5 years of

KOÇAK TUFAN et al. / Turk J Med Sci
age, adults, pregnant women, and immunocompromised
individuals [15]. Herpes simplex viruses and enteroviruses
result in viral sepsis in neonates. Other respiratory viruses
including respiratory syncytial virus, coronaviruses,
human metapneumovirus, parainfluenza virus types
1–3, adenovirus, enteroviruses, and rhinovirus can
cause severe infections. Recent studies have reported the
underestimation of sepsis cases caused by viruses [19,20].
Viral coinfections are common in respiratory infection
and may also present with a clinical picture of sepsis but
are often not considered or overlooked by clinicians.
[20]. Severe infections associated with SARS-CoV-2 have
sparked a debate or at least raised awareness about viral
sepsis, and the viral etiology has become more acceptable
as an important cause of sepsis.
3. Inflammation and cytokine storm in COVID-19
pathogenesis
3.1. Entry of the virus into cells and pathogenesis
COVID-19 may involve multiple organ systems. In
addition to the lungs, the virus has been isolated from
blood, urine, faeces, liver, and gallbladder [21,22]. The
cell entry mechanism of the virus has been extensively

researched in previous studies [23,24]. The viral entry, the
involved organs and pathogenesis of severe COVID-19 are
shown in Figure 1. SARS-CoV-2 uses human angiotensinconverting enzyme 2 (hACE2) receptors to enter the
body, and the tissues that express hACE2 receptors are
the potential target organs for the virus [25,26]. The viral
entry is triggered by the binding of receptor-binding
domain of the virus spike protein, which is responsible
for the attachment to host cells, to the hACE2 receptors,
and activated by human proteases including cell surface
protease TMPRSS2 and lysosomal proteases cathepsins
[23,27,28]. The respiratory system is the main organ of
involvement, but other hACE2 expressing tissues like the
heart, kidney, testes, and other tissues are also attacked
by the virus [29]. The precise mechanisms involved in
reaching and infecting other organs has not yet been fully
elucidated. After entry of target cells, the virus releases its
genome into the cytoplasm and initiates transcription. It
suppresses the host immune response and enhances viral
replication. In response to the virus, the host defenses are
activated with presentation of major histocompatibility
complex class I antigen. The host immune response
results in either an effective control of the infection or an

Figure 1. The cytokine storm and affected organs in COVID-19 sepsis.
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exaggerated immune response that may be deleterious to
host tissues [30]. Toll-like receptors (TLRs), which are
inflammatory receptors that are expressed in leukocytes,
vascular endothelial cells, myocardiocytes, and alveolar
type 2 cells are able to recognize pathogen components and
can trigger hyperinflammation by inducing intracellular
signaling systems such as chemokine and cytokines. It has
been suggested that polymorphisms in the genes encoding
TLRs may explain the varying spectrum of the immune
response to SARS-CoV-2, ranging from the optimal
response to exaggerated responses in COVID-19 patients
[9].
Results from autopsy series in COVID-19 patients
have demonstrated a wide range of findings including
vascular involvement, congestion, consolidation, and
hemorrhage as well as diffuse alveolar damage in lung
tissue in keeping with acute respiratory distress syndrome
(ARDS) [31]. The presence of viral cytopathic-like changes,
infiltration of inflammatory cells (mononuclear cells and
macrophages), and viral particles in histopathological
samples are considered a consequence of both direct viral
infection and immune hyperactivation. Furthermore,
immunohistochemical staining has revealed that lung
tissues such as the alveolar cavity and alveoli are infiltrated
with CD20+B cells and CD8+T cells. The severe clinical
pattern and the pathological and immunohistochemical
alterations in the lung tissues suggest that overactivation
of the immune system plays an important role in the lung
lesions alongside direct viral damage [10,32].
Thromboembolism and hyper-coagulopathy are other
components in the pathogenesis of severe COVID-19.
Various studies have revealed that significant coagulation
abnormalities occur in patients with COVID-19 and are
correlated with disease severity [33–35]. The pathogenesis
of COVID-19-associated coagulopathy is a complex series
of events. Although the pathogenesis of hypercoagulability
is not fully understood, it has been pointed out that all
three components of Virchow’s triad (endothelial injury,
stasis, and hypercoagulable state) play a major role in
contributing to clot formation in severe COVID-19
infection [36,37]. Some researchers have proposed that
severe COVID-19 is a microvascular disease in which
the virus activates endothelial inflammation and injury.
Hypercoagulability together with an inflammatory state
occurs in many patients with severe infection, and this
differs from acute DIC [37]. Thrombotic and hemorrhagic
events have been reported as common complications in
patients who have demised from SARS-CoV-2 infection.
It has been reported that sepsis-induced coagulopathy
typically occurs before disseminated intravascular
coagulation, and sepsis-induced coagulopathy and
disseminated intravascular coagulation scores have been
reported to increase over time in patients who died [38].
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3.2. Inflammation and cytokine storm
Although COVID-19 presents with mild or moderate illness
in the majority of infected patients, it may also progress
to severe respiratory infection and ARDS in 15%–20% of
cases [39,40]. An increasing number of clinical studies
indicate that a cytokine storm plays an important role in the
progression of the COVID-19 to severe infection resulting
in ARDS and multiorgan failure [41–43]. Cytokine storm
is defined as a life-threatening overactivation of immune
cells and dysregulated inflammatory cytokine/chemical
production [32]. In severe COVID-19 cases, laboratory
parameters such as hematological findings, coagulation
tests, liver function tests, D-dimer, ferritin, and acute
phase reactants such as CRP show marked alterations,
which are suggestive of a cytokine storm [6,44]. As an
immune response to viral infection, proinflammatory
cytokines and chemokines such as IL-6, IL-1, IL-18, TNF,
granulocyte-colony stimulating factor (GCS-F) have been
detected at high levels in COVID-19 patients [6–8,10].
Other cytokines have been implicated as well. In addition,
several publications have reported the detection of higher
cytokine levels in severe COVID-19 patients as compared
to nonsevere cases [8,40,43,45]. It has, therefore, been
postulated and suggested that tissue injury leading to
ARDS, and multiorgan failure in SARS-CoV-2 infection is
mainly the result of cytokine overproduction.
Another key element of COVID-19 pathogenesis
in severe cases is its similarity or association with
hemophagocytic lymphohistiocytosis (HLH). SARSCoV-2 induced cytokine storm has significant clinical
and laboratory findings overlapping with HLH. Fever,
ARDS, cytopenia, the elevation of liver function tests,
and ferritin elevations, which are common particularly in
severe COVID-19, may have developed due to secondary
HLH [8,38]. HLH is classified as primary HLH, which
has a genetic inheritance and secondary HLH. Secondary
HLH is associated with an underlying disease including,
autoimmune disease, malignancy, and viral infections
such as Epstein-Barr virus, cytomegalovirus, other herpes
viruses, and SARS-CoV-2 [38,46].
In summary, it has been proposed that SARS-CoV-2
initiates a cascade of events that results in an overreaction
of the immune system known as a cytokine storm or hyperinflammation syndrome [47]. The exact mechanism of the
cytokine storm, however, still needs to be fully elucidated.
Although the source of cytokines is not exactly known,
it has been stated that virus-infected cells such as type II
pneumonocytes and endothelial cells may be implicated
[30].
3.3. COVID-19 and Sepsis Link
From the outset of the pandemic, various reports have
indicated that although there are some unique features
pertinent to COVID-19, many of its acute manifestations are

KOÇAK TUFAN et al. / Turk J Med Sci

Multi-system
involvement

Varying/exaggerated/
dysregulated
immune response

Hyperinflammation

Cytokine storm

Hypercoagulopathy

Vascular involvement

Acute respiratory
distress syndrome

Multi-organ failure

Death

Figure 2. The clinical spectrum of sepsis in COVID-19.

similar to sepsis caused by other pathogens [10,30,48,49].
The possible spectrum of sepsis in COVID-19 are shown
in Figure 2. As has been well documented, patients
with advanced age and underlying comorbidities such
as hypertension, diabetes mellitus, chronic respiratory
failure, heart disease and impaired immune status are at
enhanced risk of more severe COVID-19, including ARDS,
multiorgan failure, and death [39,44]. This severe form of
COVID-19 disease has been related to the presence of a
cytokine storm that is suggestive of sepsis [30,50]. Liu H
et al. hypothesized that the process called viral sepsis is a
crucial step in the mechanism of COVID-19 [10]. Others
prefer the term ‘COVID-19 sepsis’ as many patients meet
the diagnostic criteria for sepsis [10,50].
SARS-CoV-2 may cause sepsis regardless of secondary
bacterial or fungal infections. Patil et al. have suggested
that the virus itself likely causes a sepsis syndrome as a
consequence of various possible mechanisms, including
immune dysregulation, respiratory dysfunction leading
to hypoxemia, and metabolic acidosis due to circulatory
dysfunction. Multiorgan failure seen in COVID-19 could
also be explained by hypoxia and circulatory disorders
that occur secondary to microvascular dysfunction.
Others have suggested that microvascular dysfunction
may also contribute to hypoxia and subsequent organ
failure through the interruption of blood flow to the lungs
by disseminated intravascular coagulation and micro-

embolism [30]. Lin HY emphasizes that various degrees
of damage to the heart, liver, kidney, and other organs in
severe infection together with laboratory abnormalities
such as decreased lymphocyte and platelet counts,
increased D-dimer, CRP, liver and myocardial enzyme
levels, and high levels of cytokines are similar to those
seen in sepsis caused by bacterial infections. He indicates
that severe COVID-19 has all the hallmarks of sepsis
including a specific pathogen and that COVID-19 should,
therefore, be considered as sepsis caused by viral infection
[49]. Other workers have reinforced this view, specifying
that all infective pathogens, including viruses can cause
sepsis [51]. Various viral respiratory pathogens, including
influenza, avian and swine flu, severe acute respiratory
syndrome (SARS), and Middle East respiratory syndrome
(MERS) have been associated with sepsis [49].
Viral sepsis has some similarities but also some
differences when compared to bacterial sepsis. In bacterial
sepsis, systemic inflammation affecting multiple organs
is more dominant than in COVID-19 sepsis [50]. While
bacterial sepsis causes an early and sudden onset clinical
deterioration, viral diseases may exhibit a relatively late
onset and chronic course [49]. Systemic steroids when used
appropriately, modulate the immune response and have
been shown to improve survival in COVID-19 patients but
are only recommended to be used to help reverse septic
shock in bacterial sepsis1[50,52]. Macrophage activation

Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L et al. Infectious Diseases Society of America Guidelines on the Treatment and Management
of Patients with COVID-19. Infectious Diseases Society of America 2021; Version 4.3.0. Available at https://www.idsociety.org/practice-guideline/covid19-guideline-treatment-and-management/. Accessed 13 June 2021.
1
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syndrome (MAS), also known as secondary HLH, is
generally more common in viral infections [50].
Consideration of severe COVID-19 disease as a
sepsis syndrome has relevance and may assist in terms of
determining treatments that will modulate the immune
response, limit intrinsic damage to tissue and organs, and
potentially improve outcome.
4. SEPSIS THERAPY IN COVID-19
4.1. General Overview and Supportive Care
The SSC has issued a guideline on the management of
critically ill patients in ICU with COVID-19 [53]. This
guideline contains 54 statements, including various
recommendations that cover aspects of infection control,
laboratory diagnosis and specimens, hemodynamic
support, ventilatory support, and COVID-19 therapy [53].
The SCC guideline has summarized its recommendations
on treatment under three main headings, hemodynamics,
ventilation, and therapy. The guideline has suggested using
dynamic parameters (skin temperature, capillary refilling
time, and/or serum lactate measurement) over static
parameters to assess fluid responsiveness. Conservative
fluid support with balanced crystalloids and using
norepinephrine (noradrenaline) as the first-line vasoactive
agent if needed, has been recommended. In the presence of
COVID-19 and refractory shock, low-dose corticosteroid

therapy (200 mg daily of hydrocortisone) is recommended.
Supplemental oxygen is recommended if peripheral
oxygen saturation is <92%. More than 75% of hospitalized
patients require supplemental oxygen therapy, and some
who do not respond to conventional oxygen therapy
may require high-flow nasal cannula (HFNC) oxygen
therapy [53]. The SCC guideline suggests use of HFNC
and noninvasive positive-pressure ventilation (NIPPV)
as options in adult COVID-19 patients with acute
hypoxemic respiratory failure. Deciding when to initiate
invasive mechanical ventilation in individuals with
respiratory failure is determined by patient condition
and characteristics [54]. Early and controlled intubation
provides better management of some risks, such as
minimizing nosocomial infections in healthcare workers
[54]. Further and more detailed information on instituting
and managing invasive mechanical ventilation is provided
in the SSC guidelines on COVID-19 and the World
Health Organization (WHO) guidelines on COVID-191
[53]. The therapeutical approach to severe COVID-19 is
summarized in Figure 3.
4.2. Specifics of therapy
4.2.1. Corticosteroids
At the beginning of the pandemic, systemic steroid
treatment was not routinely recommended in the

Hemodynamic
support

Ventilatory
support

Corticosteroids

Immunotherapy

Anticoagulant
therapy

Antimicrobia
l therapy

Figure 3. Therapeutical approach to severe COVID-19.
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management of severe COVID-19 patients2. With
subsequent better understanding and information about the
pathogenesis of COVID-19, antiinflammatory therapies,
especially corticosteroids, started to attract increasing
global attention. At present, antiinflammatory therapies
that suppress immune-mediated systemic inflammation
and the cytokine storm play a key role in the treatment of
severe COVID-19 patients. A metaanalysis on the use of
corticosteroids in adult hospitalized patients with ARDS
reported that corticosteroids may have potential benefits
on mortality, ventilation duration, and ventilation-free
days in patients with ARDS [55]. The RECOVERY Trial,
a large, multicenter, randomized, and open-label study
compared patients who received standard care with those
who received dexamethasone for up to 10 days in addition
to standard of care and found a lower mortality rate at 28
days in the dexamethasone arm of the study. This benefit
was detected in only severe and critically ill COVID-19
patients and those who required supplemental oxygen.
Patients not requiring supplemental oxygen therapy did
not experience any benefit [56]. Based on this data, it is
now accepted that corticosteroids are recommended in
severe COVID-19 patients who also meet sepsis criteria.
However, clinicians should be aware of recognized adverse
effects of corticosteroids such as hyperglycemia, secondary
infection, psychiatric disorders, and avascular necrosis.
Corticosteroids, preferably dexamethasone 6 mg IV or
per os, or 50 mg of hydrocortisone intravenously every 8
h for up to 10 days or until hospital discharge (whichever
comes first), are strongly recommended in severe and
critically ill cases of COVID-19. Corticosteroids are not
recommended in nonsevere COVID-19 cases/mild cases
and in patients not requiring oxygen therapy [57]. The
SCC guideline suggests the use of systemic steroid therapy
in mechanically ventilated adults with ARDS [53].
4.2.2. Immunotherapy
With the understanding of the role of excessive immune
response in the pathogenesis of severe COVID-19,
specific antiinflammatory drugs that suppress the immune
response in severe patients have been administered, and
the experiences with these agents have been reported.
Recent findings have shown the potential benefits of
therapies used to suppress the cytokine storm such
as anakinra and tocilizumab in secondary HLH (or
Macrophage Activation Syndrome [MAS])1. Tocilizumab,
an IL-6 receptor antagonist, has been a candidate drug
for better survival in severe patients from the early days
of the pandemic based on the evidence from studies
in which IL-6 levels were found to be higher in severe
patients compared to mild-to-moderate patients [44,58].

The RECOVERY trial reported a slight but statistically
significant improvement in survival and other clinical
outcomes with tocilizumab in COVID-19 patients with
hypoxia and systemic inflammation as compared to
standard of care [59]. The REMAP-CAP trial also reported
similar results with the IL-6 antagonists tocilizumab and
sarilumab in critically ill patients who required organ
supportive care [60]. The recommended tocilizumab dose
is 400 mg-800 mg IV (depending on weight). A second
dose may be administered 12–24 h later in the patients
whose condition has not improved [59]. Another potential
effective antiinflammatory drug for severe COVID-19 is
anakinra, an IL-1 inhibitor. IL-1 is a pro-inflammatory
cytokine and associated with severe COVID-19. Several
studies have reported improvements following anakinra
treatment based on clinical outcomes, including reduction
in mortality and reduced need for invasive mechanical
ventilation. No increase in serious side effects have been
reported [61–63].
Baricitinib, a selective Janus kinase inhibitor approved
by the US Food and Drug Administration (FDA)
for rheumatoid arthritis has also been investigated
for COVID-19 treatment. It has both antiviral and
antiinflammatory properties. A reduction in serum levels
of IL-6, IL-1β, and TNF-α, rapid recovery of circulating T
and B cell frequencies, and increased antibody production
against the SARS-CoV-2 spike protein has been reported
in severe COVID-19 cases treated with this agent [64].
Baricitinib has been advocated in select severe COVID-19
cases having elevated inflammatory markers and who
are not receiving invasive mechanical ventilation, based
on data showing a reduction in 28-day mortality. The
recommended dose is 4 mg daily dose for 14 days or until
discharge from the hospital1.
4.2.3. Anticoagulant therapy
Thromboembolism, one of the potential pathogenetic
mechanisms in the development of COVID-19 sepsis, is
common in COVID-19 cases, particularly in severe cases.
To date, various guidelines have addressed anticoagulant
therapy in COVID-193 [65–67]. Anticoagulant prophylaxis
is recommended for all hospitalized COVID-19 patients
unless contraindicated3. Most guidelines advocate
prophylactic anticoagulant drug dosing3 [65–66]. Options
for thromboprophylaxis include low molecular weight
heparin (LMWH) or unfractionated heparin, if LMWH
is unavailable. Enoxaparin is usually administered in
a dose of 40 mg by subcutaneous injection daily, with
dose adjustment for body weight and renal dysfunction.
Tinzaparin, dalteparin, and fondaparinux are the other

World Health Organization (2020). Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim
guidance, 13 March 2020. World Health Organization. https://apps.who.int/iris/handle/10665/331446. License: CC BY-NC-SA 3.0 IGO
2

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available
at https://www.covid19treatmentguidelines.nih.gov/. Accessed [13 June 2021].
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potential agents that may be used for thromboprophylaxis.
The suggested duration of thromboprophylaxis is
until discharge. Patients who are already receiving a
therapeutic dose of anticoagulant treatment should
continue on this dose of anticoagulant therapy [57].
4.2.4. Antimicrobial therapy
Viral sepsis is similar to bacterial sepsis in terms of
clinical appearance, laboratory and cytokine parameters,
and its treatment principles revolve around appropriate
supportive therapy, immune regulatory therapy, and
possibly effective antiviral treatment. Antibiotics should
not be routinely administered in COVID-19 cases. At the
beginning of the pandemic, a few small studies reported
up to 95% high coinfection rates with bacterial, fungal,
and other viral pathogens [68–69]. However, subsequent
larger studies reported much lower coinfection rates.
In an observational study from the U.S, coinfection
was observed in only 3.6% of hospitalized COVID-19
patients, whilst 79% of these patients had received
antibiotics [70]. In hospitalized COVID-19 patients,
antibiotic overuse is estimated to have contributed to an
increase in antibiotic resistance during the COVID-19
pandemic [71]. Current guidelines recommend that
antibiotics not be routinely prescribed in suspected
and confirmed COVID-19 patients in which there is a
low suspicion of a bacterial infection in order to avoid
unnecessary adverse effects and antimicrobial resistance3
[57]. In the WHO living guideline on COVID-19, the
use of empirical antibiotic therapy for likely pathogens
is recommended in cases of severe COVID-19, based
on astute clinical judgment and local epidemiology. In
this setting, antimicrobial therapy should be commenced
early (ideally within 1 h) and duration should be as short
as possible (5–7 days) [57].

4.2.5. Other therapies
Several treatment options have been investigated in severe
COVID-19. In light of the data obtained from previous
studies, routine intravenous immunoglobulins (IVIGs)
and convalescent plasma should not be used in critically ill
patients [53]. Blood filtration devices have been advocated
as a potential therapeutic approach in severe COVID-19
infection. Although viruses are not killed or destroyed by
these devices, inflammatory mediators induced by viruses
and that may be potentially harmful can be absorbed and
removed from the body [72–73]. Further studies investigating
the benefit of these treatments in severe COVID-19 patients
are needed, however, to make precise recommendations.
5. Conclusion
A considerable effort has been made since the beginning of
the pandemic to understand COVID-19, and much progress
has been made regarding its pathogenesis, epidemiology,
and clinical features. There are, however, still some unclear
points, particularly relating to the pathogenesis of severe
illness. Evidence obtained from clinical and autopsy studies
indicates that direct viral damage, infiltration of organs
with immune cells, and excessive production of cytokines
are responsible for the pathology in severe COVID-19. This
situation is similar to sepsis syndromes caused by other
pathogens. Many COVID-19 patients meet the diagnostic
criteria for sepsis, and, consequently, the basic elements
and principles of the treatment approach in COVID-19
patients should be addressed in a similar fashion to
other sepsis patients. Immunotherapies appear to play a
relevant role in the treatment of severe cases of COVID-19
consequent to an exaggerated immune response, and a
wealth of experience has accumulated over the past two
years regarding their use in COVID-19 sepsis. We will
continue to learn more over time.
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